Figure 6.
Figure 6. Gene expression and DNA binding by BRM-2 C/EBPα. (A) NE expression in GFP-sorted 32Dcl3 cells ectopically expressing p42 or BRM-2 C/EBPα. Total RNA was isolated from IL-3– or G-CSF–treated (3 days) cells. RT-PCR was performed to detect NE mRNA expression as described in “Materials and methods.” GRB2 levels are shown as a loading control. (B) EMSA of nuclear extracts (10 μg) from 6:15 cells retrovirally transduced with BRM-2 (lanes 1-7) or p42 C/EBPα (lanes 8-14) and the NE probe (wild-type or mutant) in the absence (lanes 1 and 8) or in the presence (lanes 2-6 and 9-13) of a 2- to 50-molar excess of a wild-type NE oligonucleotide used as competitor. In lanes 7 and 14, EMSAs were performed with a 32P-labeled mutant NE oligonucleotide.

Gene expression and DNA binding by BRM-2 C/EBPα. (A) NE expression in GFP-sorted 32Dcl3 cells ectopically expressing p42 or BRM-2 C/EBPα. Total RNA was isolated from IL-3– or G-CSF–treated (3 days) cells. RT-PCR was performed to detect NE mRNA expression as described in “Materials and methods.” GRB2 levels are shown as a loading control. (B) EMSA of nuclear extracts (10 μg) from 6:15 cells retrovirally transduced with BRM-2 (lanes 1-7) or p42 C/EBPα (lanes 8-14) and the NE probe (wild-type or mutant) in the absence (lanes 1 and 8) or in the presence (lanes 2-6 and 9-13) of a 2- to 50-molar excess of a wild-type NE oligonucleotide used as competitor. In lanes 7 and 14, EMSAs were performed with a 32P-labeled mutant NE oligonucleotide.

Close Modal

or Create an Account

Close Modal
Close Modal